What you don't know about choroidal melanoma

Article

Carol Shields, MD, and Jerry Shields, MD, of Wills Eye Hospital ocular oncology service shared their advice for what to look out for when it comes to choridal melanoma during a session at the American Academy of Optometry 2015 meeting in New Orleans.

New Orleans-Carol Shields, MD, of Wills Eye Hospital ocular oncology service, shared her advice for what to look out for when it comes to choridal melanoma during the Plenary Session at the American Academy of Optometry meeting in New Orleans.

More from AAO: Hot topics in dry eye and glaucoma

Choroidal nevus and melanoma

Dr.  Shields describes the relationship between choroidal nevus and melanoma as finding a rotten apple.  

“You go apple picking and among that group of fruit, there’s going to be one that goes bad. And you as eyecare specialists need to know which nevus is going to turn into melanoma,” she says. “Sometimes it’s simple; sometimes it’s very challenging.”

A recent study found that choroidal nevus occurs in approximately five percent of Caucasians and shows increasingly prevalence with age, says Dr. Shields. She estimates that most eyecare practitioners are seeing at least one patient per day with a choroidal nevus.

But that study used a database that looked only at the posterior segment of the eye-only within 45 degrees of the macula and the disc. She says that in actuality, up to 20 percent of Caucasians could have a choroidal nevus that you will have to determine whether it could be melanoma.

Dr. Shields identified a number of features that occur with choroidal nevus. These features can predict growth from nevus into melanoma:

• Nine percent have a little bit of subretinal fluid

• Six percent have overlying orange pigment

• Drusen is present in 60 percent

• Neovascularization of the choroid rarely occurs

Next: How to spot the one that will turn into melanoma

 

How to spot the one that will turn into melanoma

Dr. Shields highlights some things to keep in mind:

• A choroidal nevus can change and grow over time and still remain a nevus.

• A nevus can affect vision.

• The risk of transformation into melanoma is one in 8,845.

“So, you can reassure your patients that less than one percent turn into melanoma,” she says.

But the risk does increase with age. While patients between ages 15-19 with a nevus have a risk of one in 269,000 of transformation into melanoma, patients ages 70-74 face a risk of one in 3,000.

“You’ve got to watch those patients-I would say between ages 50 and 80, they’re at a pretty high risk for transformation,” says Dr. Shields. 

When looking for important risk factors, keep in mind, “To Find Small Ocular Melanoma Using Helpful Hints Daily,” which stands for:

Thickness greater than 2 mm

• Subretinal fluid

Symptoms

Orange pigment present

Margin within 3 mm of the optic disc

Ultrasonographic hollowness (vs. solid/flat)

Halo absent

Drusen absent

When it comes to imaging, Dr. Shields says she uses fundus photography, ultrasonography, optical coherence tomography (OCT), and autofluourescence on every patient with a choroidal nevus.

Size is one of the best indicators for the outcome. Every millimeter thicker that a melanoma grows produces a five percent increase for metastasis, says Dr. Shields, so early detection is vitally important.

“What do I see for the future? I see earlier detection using your imaging techniques, genetic testing on all patients, and better systemic therapies,” she says.

Click here to check out all of our AAO 2015 coverage

Recent Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Pediatric optometrist Dr. Magdela Stec speaks about myopia management at EyeCon 2024
Dr. Mark Dunbar chats about his EyeCon 2024 presentation about diabetic eye care
Dr. Khanh Hoang at EyeCon 2024 receiving the Visionary in Eye Care Award
Dr Adam Wenick at EyeCon 2024
David Chin Yee, MD, at EyeCon 2024
Dr. Adam Ramsey discusses innovation for your eye care practice at EyeCon 2024
Dr. Leonard Messner at EyeCon 2024
Dr. Adam Wenick at EyeCon 2024
EyeCon 2024: Insights on transforming ocular surface disease management
© 2024 MJH Life Sciences

All rights reserved.